Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Teva
Chinese Patent Office
Cantor Fitzgerald
Federal Trade Commission
Mallinckrodt
US Army
AstraZeneca
Deloitte

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,470,801

« Back to Dashboard

Which drugs does patent 8,470,801 protect, and when does it expire?

Patent 8,470,801 protects LEXISCAN and is included in one NDA.

This patent has twelve patent family members in twelve countries.
Summary for Patent: 8,470,801
Title:Myocardial perfusion imaging methods and compositions
Abstract: A myocardial imaging method that is accomplished by administering one or more adenosine A.sub.2A adenosine receptor agonist to a human undergoing myocardial imaging as well as pharmaceutical compositions comprising at least one A.sub.2a receptor agonist, at least one liquid carrier, and at least one co-solvent.
Inventor(s): Belardinelli; Luiz (Menlo Park, CA), Rosner; Mitchell (Mountain View, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:13/361,775
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 8,470,801

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD OF MYOCARDIAL IMAGING ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,470,801

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,183,226 Myocardial perfusion imaging method ➤ Try a Free Trial
8,906,878 Myocardial perfusion imaging methods and compositions ➤ Try a Free Trial
7,683,037 Myocardial perfusion imaging method ➤ Try a Free Trial
9,289,446 Myocardial perfusion imaging methods and compositions ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,470,801

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2003259264 ➤ Try a Free Trial
Canada 2492855 ➤ Try a Free Trial
China 1671399 ➤ Try a Free Trial
European Patent Office 1524984 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Federal Trade Commission
Dow
Deloitte
Fish and Richardson
Julphar
Covington
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.